2021年4月19日

ImpriMed -獸醫精密醫學領先的創業公司最近宣布,它已經關閉了總共800萬美元的項目前期融資。這些都是細節。ImpriMed -獸醫精密醫學領先的創業公司最近宣布,它已經關閉了總共800萬美元的項目前期融資770萬美元的風險投資和其他政府撥款。這一輪的資金是由HG倡議和其他參與者包括Draper Associates德雷伯龍,BonAngels,骨螺夥伴,Translink投資,底漆Sazze, FuturePlay, ES投資者。ImpriMed做什麼工作?ImpriMed利用人工智能來預測哪些抗癌藥物最有可能是有效的為特定的狗的淋巴瘤或白血病使用實時數據生成的化學敏感性和immunophenotyping化驗病人的新鮮的癌細胞。和創新的方法,使寵物癌症治療的獸醫腫瘤學家化療決策與信心,知道量化預測在實際藥物管理局藥物反應。這輪融資,ImpriMed計劃開發額外的預測模型對他們當前的目標病人犬血液癌症,擴大他們的客戶網絡,擴大管道在狗和貓其他類型的癌症。ImpriMed已經能夠臨床驗證與同行評審的期刊出版的專利技術在獸醫和比較腫瘤證明一個準確的預測減少腫瘤大小和更快的時間緩解當使用ImpriMed化療反應預測服務。到目前為止,超過2000服務已經提供給社區治療犬的病人。 KEY QUOTES: “ImpriMed is breaking new ground in medicine. Using artificial intelligence to test drugs in pets can lead to solving many diseases in pets and the company could be an onramp for breakthroughs with humans. Enormous opportunity.” — Tim Draper, Founding Partner at Draper Associates “HG Initiative along with other investors, is a welcome endorsement for ImpriMed’s AI-Driven Personalized Chemo Response Prediction tool and its viability. We look forward to all the benefits and access this funding will provide to support oncologists and pet parents to improve therapeutic options for their pets and will allow us to develop more finely tuned AI models to increase the accuracy of our service reports.” — Dr. Sungwon Lim, CEO and Co-Founder at ImpriMed